Value of baseline and end of chemotherapy ¹⁸F-FDG PET/CT in pediatric patients with Burkitt lymphoma

References

• Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012;379(9822):1234–1244.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Biggar RJ, Bhatia K, et al. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992–2005. Pediatr Blood Cancer. 2009;53(3):366–370.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/=15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–393.
   PubMed Web of Science ®Google Scholar
• Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer. 2000;82(8):1396–1402.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Meinhardt A, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124–1132.
   PubMed Web of Science ®Google Scholar
• Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Haematol. 2012;156(6):761–765.
   PubMed Web of Science ®Google Scholar
• Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–3516.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Chauvie S. Metabolic tumor volume metrics in lymphoma. Semin Nucl Med. 2018;48(1):50–66.
   PubMed Web of Science ®Google Scholar
• Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med. 2019;33(7):449–458.
   PubMed Web of Science ®Google Scholar
• Albano D, Mazzoletti A, Spallino M, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol. 2020;99(6):1321–1330.
   PubMed Web of Science ®Google Scholar
• Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46(1):87–96.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Jang S-J, Yoon DH, Kim S, et al. A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. Ann Hematol. 2012;91(12):1917–1922.
   PubMed Web of Science ®Google Scholar
• Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28(5):300–306.
   PubMed Web of Science ®Google Scholar
• Isik EG, Kuyumcu S, Kebudi R, et al. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-Point Scale and IHP criteria. Ann Nucl Med. 2017;31(9):660–668.
   PubMed Web of Science ®Google Scholar
• Bailly C, Eugène T, Couec M-L, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne). 2014;1:54.
   PubMedGoogle Scholar
• Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–3306.
   PubMed Web of Science ®Google Scholar
• Woessmann W. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2004;105(3):948–958.
   PubMed Web of Science ®Google Scholar
• Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102.
   PubMed Web of Science ®Google Scholar
• Anoop P, Sankpal S, Stiller C, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(10):1882–1888.
   PubMed Web of Science ®Google Scholar
• Fujita N, Mori T, Mitsui T, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer. 2008;51(2):188–192.
   PubMed Web of Science ®Google Scholar
• Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Societe Francaise des Cancers de l'Enfant study. Haematologica. 2015;100(6):810–817.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Jakobsen LH, Collins GP, et al. Burkitt lymphoma International Prognostic Index. J Clin Oncol. 2021;39(10):1129–1138.
   PubMed Web of Science ®Google Scholar
• Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950–956.
   PubMed Web of Science ®Google Scholar
• Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol. 2010;75(1):e68–e73.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.
   PubMed Web of Science ®Google Scholar
• Carrillo-Cruz E, Marín-Oyaga VA, Rodríguez MS, et al. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol. 2015;94(1):23–30.
   PubMed Web of Science ®Google Scholar
• Wei W-X, Huang J-J, Li W-Y, et al. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Chin J Cancer. 2015;34(3):608–613.
   PubMedGoogle Scholar
• Albano D, Bosio G, Re A, et al. Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria. Leuk Lymphoma. 2019;60(2):326–333.
   PubMed Web of Science ®Google Scholar
• Rekowski J, Hüttmann A, Schmitz C, et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-Point Scale and the ΔSUVmax method. J Nucl Med. 2021;62(1):37–42.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen Y, Huang H, et al. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544–83553.
   PubMedGoogle Scholar
• Sharma P, Gupta A, Patel C, et al. Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation. Ann Nucl Med. 2012;26(1):58–66.
   PubMed Web of Science ®Google Scholar
• Okuyucu K, Ozaydın S, Alagoz E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016;50(4):360–369.
   PubMed Web of Science ®Google Scholar
• Albano D, Bertoli M, Battistotti M, et al. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med. 2018;32(8):532–541.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu Y, Yang S, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–1098.
   PubMed Web of Science ®Google Scholar
• Chen S, He K, Feng F, et al. Metabolic tumor burden on baseline (18)F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46(9):1830–1839.
   PubMed Web of Science ®Google Scholar
• Park YS, Lee SM, Park JS, et al. Evaluating the predictive ability of initial staging F-18 FDG PET/CT for the prognosis of non-Hodgkin malignant lymphoma patients who underwent stem cell transplantation. Nucl Med Mol Imaging. 2018;52(3):216–223.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hong Z, Zhou M, et al. Prognostic value of baseline 18 F-FDG PET/CT metabolic parameters in paediatric lymphoma. J Med Imaging Radiat Oncol. 2020;64(1):87–95.
   PubMed Web of Science ®Google Scholar
• Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–1154.
   PubMed Web of Science ®Google Scholar
• Zayac AS, Evens AM, Danilov A, et al. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study. Haematologica. 2021.
   Google Scholar
• Chen B-J, Chang S-T, Weng S-F, et al. EBV-associated Burkitt lymphoma in Taiwan is not age-related. Leuk Lymphoma. 2016;57(3):644–653.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014;167(3):394–401.
   PubMed Web of Science ®Google Scholar